本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

BridgeBio Pharma, Inc.

55.29
-0.9650-1.72%
成交量:5.71万
成交额:318.71万
市值:105.70亿
市盈率:-13.51
高:56.33
开:56.21
低:55.29
收:56.26
52周最高:57.49
52周最低:21.72
股本:1.91亿
流通股本:1.51亿
量比:0.31
换手率:0.04%
股息:- -
股息率:- -
每股收益(TTM):-4.0935
每股收益(LYR):-2.8793
净资产收益率:-1789.67%
总资产收益率:-41.96%
市净率:-5.91
市盈率(LYR):-19.20

数据加载中...

2025/01/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

重要事件披露

Form 8-K - Current report
2024/11/25

重要事件披露

Form 8-K - Current report
2024/11/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/12

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/11/06

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/17

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/09/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/11

重要事件披露

Form 8-K - Current report
2024/08/21

重要事件披露

Form 8-K - Current report
2024/08/20

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/08/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/01

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/01

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/01

重要事件披露

Form 8-K - Current report
2024/07/23

重要事件披露

Form 8-K - Current report